Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACI.0000000000000985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper.
J Allergy Clin Immunol
December 2024
Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, University of Cincinnati, Cincinnati, Ohio.
Background: There is no global agreement on the definition of chronic spontaneous urticaria (CSU) remission.
Objective: Our aim was to generate a consensus for clinical definitions of CSU-related terms focused on remission.
Methods: The World Allergy Organization Urticaria Committee systematically reviewed current available longitudinal articles.
Omalizumab is the Columbus egg for food allergies.
Curr Opin Allergy Clin Immunol
June 2024
NHO Sagamihara National Hospital, Tokyo, Japan.
Choosing biologics for uncontrolled asthma: A conundrum for clinicians.
Ann Allergy Asthma Immunol
May 2023
Division of Allergy & Immunology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio. Electronic address:
An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
J Allergy Clin Immunol Pract
May 2022
Division of Allergy and Immunology, Northwestern University, Chicago, Ill. Electronic address:
Background: Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality.
Objective: To examine real-world practice data to describe the safety and consequences of various biologics suspected to directly or indirectly affect eosinophilic inflammation for the treatment of HES.
The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.
World Allergy Organ J
June 2021
Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, México.
This is Part 1 of an updated follow-up review of a World Allergy Organization (WAO) position paper published in 2012 on the diagnosis and treatment of urticaria and angioedema. Since 2012, there have been advances in the understanding of the pathogenesis of chronic urticaria, and greater experience with the use of biologics, such as omalizumab, in patients with severe refractory disease. For these reasons, the WAO decided to initiate an update targeted to general practitioners around the world, incorporating the most recent information on epidemiology, immunopathogenesis, comorbidities, quality of life, clinical case presentations, and the management of chronic spontaneous and chronic inducible urticaria, including urticaria in special situations such as childhood and pregnancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!